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lent alternative source of MSCs. The aim of this study was to
compare different enrichment methods of obtaining MSCs from
CB, to generate sufﬁcient numbers of MSCs for transplantation.
The plastic adhesion method (PAM) and the depleting method
RosetteSep (DMR) on fresh CB units were compared. Both cell
fractions were grown in Mesencult complete medium. Their pro-
liferative capacity and their phenotype during culture were tested.
The MSC phenotype was evaluated by expression of CD105,
glycophorin A, CD29, CD44, CD45, CD31, CD34, CD64,
CD62L, CD106, CD117, CD133, CD90, HLA-class I, HLA-DR,
CD1a, CD3, CD51, and CD58. Sufﬁcient numbers of cells (56.6
9.2%) were recovered after the PAM and only a few cells (5.3 
2.6%) were isolated from the whole CB using the DMR. After the
second passage, the PAM allowed 155.5  62.9% of MSCs to be
obtained, whereas 108.3  0.99% of MSCs were obtained by the
DMR. For both methods, 3 passages were needed to obtain com-
parable homogeneity, corresponding to an average of 45 days. The
CB-derived MSCs were positive for the matrix receptors CD44,
CD58, and CD105; the integrins CD29 and CD51; and the mark-
ers CD90 and HLA-class I. They were negative for the matrix
receptors CD31 and CD62L, as well as the hematopoietic markers
CD45, CD34, CD133, CD64, CD117, CD1a, CD3, and HLA-
DR. In conclusion, both methods may represent an easy way of
obtaining MSCs from CB with the aim of potential use in CB
transplantation, because MSCs facilitate and promote the overall
engraftment level of multidonor CB grafts.
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WEIGHT LOSS IN PEDIATRIC PATIENTS WITH CHRONIC GRAFT-VER-
SUS-HOST DISEASE (CGVHD)
Browning, B., Thormann, K., Tse, W., Duerst, R., Kletzel, M.,
Jacobsohn, D.A. Children’s Memorial Hospital, Northwestern Univer-
sity, Chicago, IL.
Weight loss and malnutrition are major problems in patients with
cGVHD. In adults, a low body mass index (BMI) is a predictor for
mortality; however, weight loss and BMI have not been studied in
pediatric patients with cGVHD. A retrospective study of 18 pa-
tients at Children’s Memorial Hosptial with extensive cGVHD
based on the revised Seattle Classiﬁcation was completed. Median
age at SCT was 11.5 years (range, 1–22 years); age at cGVHD
diagnosis was 12 years (range, 1–23 years). Median duration of
immunsuppressive therapy was 15.5 months (range, 3–51 months).
Maximum height, weight, and BMI change were calculated from
date of SCT through the duration of cGVHD treatment. Patients
were also graphed on standard growth charts. Patients were strat-
iﬁed into groups based on the number of organ systems involved.
Patients with multiorgan involvement had a mean maximal BMI
decrease of &minus9%, and 50% of these patients had a decrease
of 1–4 quintiles on standard weight-for-age growth charts and
remain at less than the 10th percentile in expected weight for age.
This change in BMI not only indicates a signiﬁcant decrease in
weight but also often a plateau in stature. The resolution of oral
and GI symptoms did not appear to reverse this weight loss trend,
which indicates a structural alteration in the GI tract or an in-
creased metabolic rate. All of the patients with multiorgan involve-
ment required salvage therapy beyond steroids and CSA, and 3 of
them died due to complications of cGVHD. All patients with
single organ involvement have resolved their cGVHD with stan-
dard therapy. Weight loss and malnutrition are clinically signiﬁ-
cant issues in pediatric patients with multisystem cGVHD. Weight
loss is likely another systemic manifestation of the disease and may
contribute to increased mortality in this group. Studies measuring
resting energy expenditure and intestinal permeability are under-
way to further understand the nature of weight loss in this popu-
lation.
>1 Organ Involved 1 Organ Involved P
Number of
patients
11 7
Age at HSCT 10.2 years
(5.7–14.5)
14.5 years
(11.8–17.3)
0.1
Age at cGVHD
diagnosis
10.5 years
(5.8–15)
14.7 years
(12.1–17.3)
0.14
Length of therapy 19.5 months
(10.9–28.1)
14.2 months
(12.2–16.3)
0.3
Sites of
involvement
Skin/MS 11/11 2/7 0.002
Liver 3/11 5/7 0.08
Oral 7/11 0/7 0.01
GI 2/11 0/7 0.3
Lung 1/11 0/7 0.6
Max BMI change 9% (17.6%–1.2%) 10.2% (2%–20.8%) 0.003
Max weight
change
4% (13%–5%) 14.8% (2.2%–27.4%) 0.01
Median # quintiles
dropped
1.5 (0-4) 0 (0-0) —
Weight under
25%ile
6/10 0/7 0.01
Weight under
10%ile
5/10 0/7 0.04
Deaths 3/11 0/7 0.2
Continuous variables expressed as mean with 95% CI unless where
noted. Frequencies are compared using Fisher’s exact test.
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EVALUATION OF ORAL MUCOSITIS USING A SELF-REPORTED QUES-
TIONNAIRE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UN-
DERGOING HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY PE-
RIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION
Stiff, P.J.1, Bensinger, W.I.2, Emmanouilides, C.3, Gentile, T.4,
Okano, G.5, Lu, J.5, Erder, M.H.6, Spielberger, R.7 1Loyola University,
Maywood, IL; 2Fred Hutchinson Cancer Research Center, Seattle, WA;
3UCLA Medical Center, Los Angeles, CA; 4SUNY Upstate Medical
University, Syracuse, NY; 5Amgen, Inc., Thousand Oaks, CA; 6Forest
Laboratories, Inc., Jersey City, NJ; 7City of Hope National Medical
Center, Duarte, CA.
Background: Oral mucositis (OM) is a frequent complication
experienced by patients with hematologic malignancies (HMs)
undergoing high-dose chemoradiotherapy (CRT) followed by pe-
ripheral blood progenitor cell transplantation (PBPCT). Patients
rate OM as the most debilitating side effect of hematologic trans-
plantation. In clinical trials, physicians assess the severity of OM
using 1 or more established clinical scales such as the WHO,
WCCNR, or RTOG. In a pivotal phase 3 randomized, placebo-
controlled, double-blind clinical trial of palifermin (a rHuKGF
molecule) in HM patients, patients assessed their OM severity and
impact on daily functions through a self-reported OM daily ques-
tionnaire (OMDQ). We compared these patient self-reporting
results with established clinical OM scales (WHO, WCCNR, and
RTOG) and report the ﬁndings here. Methods: Over a period of
40 days, patient reported mouth and throat soreness (MTS) and its
impact on swallowing, eating, drinking, talking, and sleeping
(MTS-AL) were assessed daily using the OMDQ in 212 patients
(placebo, n  106; palifermin, n  106). The mean daily compli-
ance rate for completing the self-reporting questionnaires over the
entire study period was 84% in the placebo group and 89% in the
palifermin group. The Pearson correlation coefﬁcients between
MTS/MTS-AL scores and clinical OM scales at days 7 and 14
posttransplantation and between the change in scores in MTS/
MTS-AL and clinical OM scales between days 7 and 14 posttrans-
plantation were calculated. The daily OM severity grades, as mea-
sured by OMDQ, WHO, WCCNR, and RTOG, were graphed
for comparison. Results: Patients were able to detect the increases
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